| 產(chǎn)品編號 | BIO0946SM |
| 英文名稱 | Anti-CD3 & CD20 Reference Antibody (Epcoritamab Biosimilar) |
| 中文名稱 | |
| 別 名 | CD20 & CD3; Epcoritamab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.28 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Epcoritamab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Epcoritamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.009 nM.
Epcoritamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to Raji cells, and the EC50 was 8.393 nM.
Epcoritamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to huCD3e-jurkat cells, and the EC50 was 18.920 nM.
Epcoritamab bound to CD20 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD20-VLP, and the EC50 was 0.095 nM.
Epcoritamab bound to CD3e protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD3e-Fc, and the EC50 was 0.024 nM.
The purity of Anti-CD3 & CD20 Reference Antibody (Epcoritamab) is more than 99.00%, determined by SEC-HPLC.
Anti-CD3 & CD20 Reference Antibody (Epcoritamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
